Chemistry:Tegomil fumarate
 | |
| Clinical data | |
|---|---|
| Trade names | Riulvy |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H26O11 |
| Molar mass | 418.395 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tegomil fumarate sold under the brand name Riulvy, is a medication used for the treatment of relapsing remitting multiple sclerosis.[1] It is taken by mouth.[1]
The mechanism of action of tegomil fumarate is not fully understood but it is thought to act via its main active metabolite monomethyl fumarate.[1] This metabolite activates the NRF2 transcriptional pathway, which reduces inflammation and modulates the activity of immune cells, thereby protecting the cells of the central nervous system from damage.[1]
Tegomil fumarate was authorized for medical use in the European Union in July 2025.[2]
Medical uses
Tegomil fumarate is indicated for the treatment of people aged thirteen years of age and older with relapsing remitting multiple sclerosis.[1]
Society and culture
Legal status
In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Riulvy, intended for the treatment of adults and children from 13 years of age with relapsing remitting multiple sclerosis.[1] The applicant for this medicinal product is Neuraxpharm Pharmaceuticals, S.L.[1] Riulvy is a hybrid medicine of Tecfidera, which has been authorized in the EU since January 2014.[1] Riulvy contains a different active substance but acts via the same active metabolite as Tecfidera, monomethyl fumarate.[1] Tegomil fumarate was authorized for medical use in the European Union in July 2025.[1][2]
Names
Tegomil fumarate is the international nonproprietary name.[3]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Riulvy EPAR". 23 May 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/riulvy. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 2.0 2.1 2.2 "Riulvy PI". 7 August 2025. https://ec.europa.eu/health/documents/community-register/html/h1947.htm.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information 38 (1). 2024.
 |  |
